Completed PHASE3 INTERVENTIONAL 1-arm NCT00115076

Study of the Drug Efalizumab (Raptiva), for Adult Patients With Moderate to Severe Plaque Psoriasis

A Phase IIIB Study to Evaluate the Mechanism of Action of 1.0 mg/kg Subcutaneously Administered Efalizumab in Adults With Moderate to Severe Plaque Psoriasis Who Are Candidates for Systemic Therapy

Sponsor: Genentech, Inc.

Conditions Psoriasis

Interventions Efalizumab

Updated 9 times since 2017 Last updated: Feb 4, 2021 Started: Aug 4, 2003 Primary completion: May 18, 2009 Completion: Apr 6, 2011

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00115076, this PHASE3 trial focuses on Psoriasis and remains completed. Sponsored by Genentech, Inc., it has been updated 9 times since 2003, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

9 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2023 — Jul 2024 [monthly]

Completed PHASE3
Dec 2022 — Jan 2023 [monthly]

Completed PHASE3
Mar 2021 — Dec 2022 [monthly]

Completed PHASE3

▶ Show 4 earlier versions

Jan 2021 — Mar 2021 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3
Feb 2017 — Jun 2018 [monthly]

Completed PHASE3
Jan 2017 — Feb 2017 [monthly]

Completed PHASE3

First recorded

Aug 2003

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Genentech, Inc.
Rockefeller University

Data source: Rockefeller University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• New York, United States